Nuveen’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.05B Buy
8,336,930
+503,366
+6% +$66.3M 0.25% 77
2026
Q1
$1.09B Buy
7,833,564
+1,519,508
+24% +$213M 0.3% 65
2025
Q4
$775M Buy
6,314,056
+368,303
+6% +$44.8M 0.2% 90
2025
Q3
$660M Buy
5,945,753
+91,500
+2% +$10.4M 0.17% 103
2025
Q2
$649M Buy
5,854,253
+317,309
+6% +$33.8M 0.18% 99
2025
Q1
$620M Buy
5,536,944
+328,623
+6% +$33.9M 0.19% 101
2024
Q4
$481M Buy
5,208,321
+724,493
+16% +$65.2M 0.14% 128
2024
Q3
$376M Sell
4,483,828
-502,589
-10% -$38.3M 0.11% 161
2024
Q2
$342M Sell
4,986,417
-3,584,153
-42% -$239M 0.1% 161
2024
Q1
$628M Sell
8,570,570
-2,964,905
-26% -$228M 0.19% 109
2023
Q4
$934M Buy
11,535,475
+121,326
+1% +$9.44M 0.3% 68
2023
Q3
$855M Buy
11,414,149
+1,614,798
+16% +$124M 0.3% 70
2023
Q2
$755M Buy
9,799,351
+530,242
+6% +$42.3M 0.26% 79
2023
Q1
$769M Buy
9,269,109
+614,202
+7% +$50.9M 0.29% 83
2022
Q4
$743M Buy
8,654,907
+663,387
+8% +$52.5M 0.29% 83
2022
Q3
$493M Buy
7,991,520
+1,123,549
+16% +$70.8M 0.2% 104
2022
Q2
$425M Sell
6,867,971
-766,659
-10% -$47.5M 0.16% 127
2022
Q1
$455M Sell
7,634,630
-1,361,924
-15% -$87.1M 0.15% 135
2021
Q4
$653M Sell
8,996,554
-278,343
-3% -$19.2M 0.19% 114
2021
Q3
$648M Buy
9,274,897
+407,151
+5% +$28.6M 0.2% 104
2021
Q2
$611M Buy
8,867,746
+148,891
+2% +$9.94M 0.18% 114
2021
Q1
$564M Buy
8,718,855
+3,918,666
+82% +$253M 0.18% 116
2020
Q4
$280M Buy
4,800,189
+55,306
+1% +$3.34M 0.09% 197
2020
Q3
$300M Sell
4,744,883
-1,626,848
-26% -$113M 0.12% 170
2020
Q2
$490M Sell
6,371,731
-6,067,783
-49% -$465M 0.2% 96
2020
Q1
$930M Buy
12,439,514
+4,135,434
+50% +$286M 0.45% 47
2019
Q4
$540M Sell
8,304,080
-1,512,563
-15% -$98.5M 0.2% 107
2019
Q3
$622M Sell
9,816,643
-30,716
-0.3% -$2.01M 0.25% 82
2019
Q2
$665M Buy
9,847,359
+9,094,586
+1,208% +$598M 0.26% 77
2019
Q1
$48.9M Buy
752,773
+188,180
+33% +$12.5M 0.26% 73
2018
Q4
$35.3M Sell
564,593
-65,430
-10% -$4.57M 0.22% 104
2018
Q3
$48.6M Buy
630,023
+4,153
+0.7% +$314K 0.26% 88
2018
Q2
$44.3M Sell
625,870
-59,721
-9% -$4.22M 0.28% 86
2018
Q1
$51.7M Sell
685,591
-290,812
-30% -$23.1M 0.34% 59
2017
Q4
$70M Buy
976,403
+116,003
+13% +$8.81M 0.45% 42
2017
Q3
$69.7M Buy
860,400
+152,293
+22% +$11.6M 0.46% 42
2017
Q2
$50.1M Buy
708,107
+10,669
+2% +$710K 0.32% 65
2017
Q1
$47.4M Sell
697,438
-96,733
-12% -$6.8M 0.28% 84
2016
Q4
$56.9M Buy
794,171
+133,289
+20% +$9.91M 0.29% 80
2016
Q3
$52.3M Sell
660,882
-37,966
-5% -$3.08M 0.31% 78
2016
Q2
$58.3M Sell
698,848
-57,810
-8% -$5.13M 0.36% 61
2016
Q1
$69.5K Buy
756,658
+33,092
+5% +$2.98M 0.36% 46
2015
Q4
$73.2K Sell
723,566
-184
-0% -$19.1K 0.38% 41
2015
Q3
$71.1K Sell
723,750
-17,918
-2% -$1.99M 0.4% 40
2015
Q2
$86.8K Sell
741,668
-4,225
-0.6% -$462K 0.47% 31
2015
Q1
$73.2M Sell
745,893
-25,639
-3% -$2.6M 0.4% 43
2014
Q4
$72.7M Buy
771,532
+107,869
+16% +$11.2M 0.41% 42
2014
Q3
$70.6M Sell
663,663
-29,920
-4% -$2.93M 0.43% 44
2014
Q2
$57.5M Sell
693,583
-147,692
-18% -$11.5M 0.35% 55
2014
Q1
$59.6M Buy
841,275
+16,036
+2% +$1.26M 0.36% 47
2013
Q4
$62M Sell
825,239
-143,109
-15% -$9.96M 0.4% 44
2013
Q3
$60.9M Sell
968,348
-88,606
-8% -$5.3M 0.39% 52
2013
Q2
$54.2M Buy
+1,056,954
New +$55.1M 0.36% 51

Other funds holding GILD

Nuveen's GILD Position: Q2 2026 in Review

Nuveen increased its Gilead Sciences (GILD) stake by 6.4% in Q2 2026, buying an estimated $66.3M and bringing the position to 8,336,930 shares worth $1.05B. The position accounts for 0.25% of the portfolio, ranked #77.

Nuveen first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.09B in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Nuveen held 8,336,930 shares of Gilead Sciences worth $1.05B as of Q2 2026.
  • Nuveen bought 503,366 Gilead Sciences shares in Q2 2026, an estimated $66.3M.
  • Gilead Sciences made up 0.25% of Nuveen's portfolio in Q2 2026, its #77 holding.
  • Nuveen first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's Gilead Sciences position peaked at $1.09B in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.